AF
SYRE icon

Allworth Financial’s Spyre Therapeutics SYRE Stock Holding History

Allworth Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Buy
226
+109
+93% +$7.95K ﹤0.01% 3197
2026
Q1 		$5.9K Buy
117
+59
+102% +$2.22K ﹤0.01% 3859
2025
Q4 		$1.9K Buy
58
+26
+81% +$679 ﹤0.01% 4138
2025
Q3 		$537 Buy
32
+2
+7% +$33 ﹤0.01% 4416
2025
Q2 		$450 Buy
30
+17
+131% +$252 ﹤0.01% 4164
2025
Q1 		$195 Buy
13
+4
+44% +$83 ﹤0.01% 3876
2024
Q4 		$197 Buy
9
+2
+29% +$59 ﹤0.01% 3792
2024
Q3 		$206 Buy
+7
New +$195 ﹤0.01% 3592

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Allworth Financial's SYRE Position: Q2 2026 in Review

Allworth Financial increased its Spyre Therapeutics (SYRE) stake by 93% in Q2 2026, buying an estimated $7.95K and bringing the position to 226 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

Allworth Financial first reported a position in SYRE in Q3 2024 and has held it in 8 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Allworth Financial held 226 shares of Spyre Therapeutics worth $20.1K as of Q2 2026.
  • Allworth Financial bought 109 Spyre Therapeutics shares in Q2 2026, an estimated $7.95K.
  • Spyre Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3197 holding.
  • Allworth Financial first reported a position in Spyre Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.